Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody.
We identified the domains of CD26 involved in the binding of Middle East respiratory syndrome coronavirus (MERS-CoV) using distinct clones of anti-CD26 monoclonal antibodies (MAbs). One clone, named 2F9, almost completely inhibited viral entry. The humanized anti-CD26 MAb YS110 also significantly inhibited infection. These findings indicate that both 2F9 and YS110 are potential therapeutic agents for MERS-CoV infection. YS110, in particular, is a good candidate for immediate testing as a therapeutic modality for MERS.
Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Hongo, Bunkyo-ku, Tokyo, Japan.
Kei
K
Ohnuma
Bart L
BL
Haagmans
Ryo
R
Hatano
V Stalin
VS
Raj
Huihui
H
Mou
Satoshi
S
Iwata
Nam H
NH
Dang
Berend Jan
BJ
Bosch
Chikao
C
Morimoto
D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000494:pharmacology; D000914:Antibodies, Viral / Q000276:immunology* / Q000494:pharmacology; D003332:Coronaviridae / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D003333:Coronaviridae Infections / Q000188:drug therapy / Q000201:enzymology* / Q000276:immunology / Q000821:virology*; D018819:Dipeptidyl Peptidase 4 / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D018604:Epitope Mapping; D006801:Humans; D011485:Protein Binding; D017434:Protein Structure, Tertiary; D064370:Spike Glycoprotein, Coronavirus / Q000235:genetics / Q000378:metabolism; D053586:Virus Internalization / Q000187:drug effects
D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D064370:Spike Glycoprotein, Coronavirus; D018819:Dipeptidyl Peptidase 4